Catheter Precision Announces September 10th, 2025 Record Date for October 10th, 2025 Special Meeting of Stockholders
VTAK(VTAK) FORT MILL, S.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that September 10th, 2025, is the Record Date for the October 10th Special Meeting of the stockholders. We are seeking stockholder approval to amend our Certificate of Incorporation to increase our authorized shares of common stock, and to appoint WithumSmith+Brown, PC as our independent auditor for our fiscal year 2026. Additional details are available in the preliminary proxy statement anticipated to be filed with the SEC on September 4th, 2025.
Catheter Precision Announces First Procedures in France as LockeT Expansion Continues
VTAKFORT MILL, S.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company and leader in innovative cardiac electrophysiology solutions, is proud to announce the first LockeT procedures in France. This milestone demonstrates significant progress in the adoption and commercialization of its technologies across the continent.
Catheter Precision, Inc. Announces Effectiveness of 1-for-19 Reverse Stock Split
VTAKFORT MILLS, S.C., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, announced today that its previously announced 1-for-19 reverse stock split of its common stock became effective at 12:01 A.M. Eastern Time, on August 15, 2025. The Company's common stock will continue to be traded on the NYSE American under the symbol "VTAK" and will begin trading on a split-adjusted basis when the market opens on August 15, 2025. The new CUSIP number for the Company's common stock following the reverse stock split will be 74933X708.
First LockeT Cases Completed in Germany
VTAKFORT MILL, S.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that the first LockeT cases were recently completed in Germany at Zentralklinik Bad Berka. With a total of 20 clinics and specialist departments, it is one of the largest hospitals in Thuringia.
Catheter Precision Addresses Increased Trading Activity, Reaffirms Strategic Plans
VTAKCatheter Precision Addresses Increased Trading Activity, Reaffirms Strategic Plans
VTAKCatheter Precision Receives CE Mark Approval For Advanced Vascular Closure Device LockeT
VTAKCatheter Precision Files For Resale Of Up To 12.9M Shares Of Common Stock By The Selling Stockholders
VTAKCatheter Precision Enters At Market Offering Agreement With Ladenburg Thalmann & Co; May Sell Up To $1.3M In Common Stock
VTAKCatheter Precision, Inc. Common Stock Q1 EPS $(0.36) Misses $(0.20) Estimate, Sales $143.00K Miss $300.00K Estimate
VTAKCatheter Precision Negotiating Asset Purchase Agreement With Cardionomic
VTAKCatheter Precision Files For Mixed Shelf Of Up To $20M
VTAKCatheter Precision Receives Purchase Order For LockeT From Montefiore Medical Center
VTAKCatheter Precision Announces That New Clinical Data From The VIVO EU Registry Was Presented Last Week At The Society Of Cardiac Robotic Navigation Meeting; 17 (≈95%) Patients Had Successful Ablation Procedures; 83% Of Patients Had No Recurrence Of The Arr
VTAK